Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe page shows an updated revision from v3.3.1 to v3.3.2, indicating a minor update to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoChange DetectedAdded revision label v3.3.1 and removed revision label v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedFunding-status notice at the bottom of the page was removed. The core study content, including objectives, eligibility criteria, and outcome measures, remains unchanged.SummaryDifference0.4%

- Check34 days agoChange DetectedNo significant changes detected between the two page states; only minor visual differences are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check63 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%

- Check70 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.